Literature DB >> 17222614

Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.

R Houston Thompson1, Bradley C Leibovich, Christine M Lohse, John C Cheville, Horst Zincke, Michael L Blute, Igor Frank.   

Abstract

PURPOSE: To date all prediction models for patients with renal cell carcinoma have estimated outcome in static fashion starting from the date of surgery only. We created a dynamic outcome prediction model for continual surveillance that accounts for the disease-free interval following surgery.
MATERIALS AND METHODS: We identified 1,560 patients treated with radical nephrectomy for pM0 clear cell renal cell carcinoma between 1970 and 1999. The previously published stage, size, grade and necrosis score was used to stratify patients according to the risk of death from renal cell carcinoma. Cancer specific survival rates were calculated using the Kaplan-Meier method at surgery and at various disease-free intervals following surgery.
RESULTS: At last followup 461 of the 1,560 patients had died of renal cell carcinoma at a median of 3.1 years following surgery. Median followup in patients still alive was 11.2 years. Patient outcome improved as the disease-free interval following surgery increased. For example, patients with a stage, size, grade and necrosis score of 5 had an estimated 5-year cancer specific survival rate of 69.6% at surgery. However, those who survived without disease for 1, 2 and 3 years following surgery had adjusted estimated 5-year cancer specific survival rates of 81.9%, 91.9% and 93.2%, respectively. Patients with a stage, size, grade and necrosis score of 7 had a 5-year cancer specific survival rate of 44.9% at surgery, which increased to 63.3%, 71.0% and 72.8% after 1 to 3 years of disease-free followup, respectively.
CONCLUSIONS: Within each stage, size, grade and necrosis score cancer specific survival rates increase as the disease-free interval following surgery increases. We present a dynamic outcome prediction model that allows clinicians to continually adjust surveillance as the disease-free interval increases.

Entities:  

Mesh:

Year:  2007        PMID: 17222614     DOI: 10.1016/j.juro.2006.09.057

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  [Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].

Authors:  M May; F Kendel; B Hoschke; C Gilfrich; S Kiessig; S Pflanz; M Seidel; S Brookman-Amissah
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

2.  Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Authors:  Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.

Authors:  Byron H Lee; Andrew Feifer; Michael A Feuerstein; Nicole E Benfante; Lei Kou; Changhong Yu; Michael W Kattan; Paul Russo
Journal:  Eur Urol Focus       Date:  2016-07-28

4.  Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

Authors:  A Ari Hakimi; Irina Ostrovnaya; Boris Reva; Nikolaus Schultz; Ying-Bei Chen; Mithat Gonen; Han Liu; Shugaku Takeda; Martin H Voss; Satish K Tickoo; Victor E Reuter; Paul Russo; Emily H Cheng; Chris Sander; Robert J Motzer; James J Hsieh
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 5.  Percutaneous biopsy for risk stratification of renal masses.

Authors:  Michael L Blute; Anna Drewry; Edwin Jason Abel
Journal:  Ther Adv Urol       Date:  2015-10

6.  The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma.

Authors:  A Ari Hakimi; Ling Chen; Philip H Kim; Daniel Sjoberg; Leonard Glickman; Marc R Walker; Paul Russo
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

7.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

Review 8.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

9.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

Review 10.  Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.

Authors:  Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.